CDXC:NSD-ChromaDex Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.00

Change

-0.99 (-9.91)%

Market Cap

USD 0.68B

Volume

1.18M

Average Target Price

USD 15.00 (+66.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-3.28 (-1.62%)

USD81.30B 135.70 104.16
REGN Regeneron Pharmaceuticals, Inc

+1.91 (+0.36%)

USD57.11B 15.26 11.77
BNTX BioNTech SE

-1.78 (-0.83%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

-0.51 (-0.27%)

USD48.76B 17.95 12.38
ALXN Alexion Pharmaceuticals, Inc

+0.72 (+0.40%)

USD39.91B 58.41 42.10
BGNE BeiGene, Ltd

-7.33 (-2.23%)

USD30.29B N/A N/A
GMAB Genmab A/S

-0.61 (-1.40%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.93 (+1.91%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

-0.11 (-0.25%)

USD26.79B 22.60 15.62
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CDXC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 87.50% 91% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.50% 91% A- 93% A
Trailing 12 Months  
Capital Gain 92.72% 82% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.72% 82% B- 80% B-
Trailing 5 Years  
Capital Gain 80.72% 66% D 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.72% 66% D 59% F
Average Annual (5 Year Horizon)  
Capital Gain 27.79% 60% D- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.79% 60% D- 74% C
Risk Return Profile  
Volatility (Standard Deviation) 57.94% 54% F 30% F
Risk Adjusted Return 47.96% 73% C 67% D+
Market Capitalization 0.68B 62% D- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.95 10% F 8% F
Price / Cash Flow Ratio -64.02 94% A 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -70.90% 40% F 16% F
Return on Invested Capital -107.70% 16% F 6% F
Return on Assets -26.68% 43% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.27 36% F 19% F
Short Percent 9.49% 35% F 21% F
Beta 1.68 32% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector